Department: Translational and Biomarker Research, Oncology Platform
Title: Group Leader
Start Date: May 16, 2011
Education: B.A. Biology, College of the Holy Cross (1991), Ph.D. Molecular Biology, Princeton University (1996), Postdoctoral: Whitehead Institute, MIT (2001)
What initially drew you to EMD Serono?
I was drawn to EMD Serono by the world-class science and excellent portfolio of oncology programs in R&D, which include small molecules, antibodies and protein therapeutics.
What do you like about working for this organization?
I enjoy collaborating with and learning from top cancer researchers and oncologists in a global organization.
What makes EMD Serono unique?
EMD Serono’s R&D organization is willing to take risks on more challenging targets and therapeutic modalities that require innovative solutions.
What do you enjoy most about working as a researcher?
I enjoy communicating with and learning from people with a wide range of different backgrounds and expertise in the areas drug discovery, biomarkers and clinical development.
Please describe your career path.
During my Ph.D. work, I studied the mechanisms by which the p53 tumor suppressor, the most frequently mutated gene in human cancer, transforms cells. I then did postdoctoral research in the laboratory of Dr. Robert Weinberg at the Whitehead Institute where I developed a genetically-defined model of breast cancer with a set of 3 oncogenes and found an important role for the tumor stroma in cancer development in this model. I then worked in the Oncology Department at Biogen Idec for 10 years where I led a Raf kinase inhibitor project from early discovery into a Phase I clinical trial that began in 2011.